Small-molecule therapy developer Xgene Pharma has received $20m in a Ping An Ventures-led round that also featured a subsidiary of Sinar Mas.

Ping An Ventures, the corporate venturing arm of insurance group Ping An, has led a $20m series B round for China-based pharmaceuticals developer Xgene Pharma, ChinaBio Today has reported.

Zhongtai Investment, a subsidiary of diversified conglomerate Sinar Mas, also took part in the round, as did life sciences-focused venture capital firm TF Capital and Morningside Venture Capital, a subsidiary of investment firm Morningside Group.

Founded in 2016, Xgene Pharma is working on small-molecule drugs to help fight chronic pain, infectious…